Vaccines for poverty-related diseases – 2016
Under this call, large-scale collaborative projects are supported that include one or more clinical trials (phase I to IV) aiming to accelerate the clinical development of new vaccines (preventive or therapeutic) against one of the poverty-related infectious diseases. Applications included at least one clinical trial to be carried out in sub-Saharan Africa in order to test the safety, immunogenicity and/or efficacy of the vaccine(s).
Call identifier: RIA2016V
See the corresponding call for proposals
MMVC
Multi-stage malaria vaccine consortium: field efficacy testing of a multi-stage malaria vaccine
Chancellor, Masters and Scholars of the University of Oxford (UOXF) with partners from Burkina Faso, France, Germany, India, Netherlands, Sierra Leone, Sweden, Tanzania, and United Kingdom
Project coordinator: Prof. Adrian V.S. Hill, Nuffield Department of Medicine (UOXF), United Kingdom
Starting date: 1 April 2018
Duration: 66 months
Grant amount: EUR 15,000,000
Grant agreement: RIA2016V-1649
ERA-Learn project webpage
MTBVAC-Newborns
MTBVAC in Newborns: Phase 2a dose-defining safety and immunogenicity study and capacity building to support vaccine efficacy trials in tuberculosis-endemic regions of sub-Saharan Africa
Biofabri S.L., Pontevedra, Spain with partners from Madagascar, Netherlands, Senegal, South Africa, Spain
Project coordinator: Ms Ingrid Murillo, Biofabri S.L., Spain
Starting date: 1 January 2018
Duration: 52 months
Grant amount: EUR 5,537,093
Grant agreement: RIA2016V-1637
Project web page on TBVI website
NIFTY
Non-inferiority of fractional-doses trial for yellow fever vaccine
Chancellor, Masters and Scholars of the University of Oxford (UOXF) with partners from France, Senegal,and Uganda
Project coordinator: Prof. Philip Bejon (UOXF), KEMRI-Wellcome, Kenya
Starting date: 1 April 2018
Duration: 40 months
Grant amount: EUR 3,235,731
Grant agreement: RIA2016V-1633
POR TB
POR TB consortium: phase 2 trial to determine efficacy of the multistage vaccine H56:IC31 for prevention of recurrent TB disease
Statens Serum Institut (SSI), Copenhagen, Denmark with partners from Italy, South Africa, and Tanzania
Project coordinator: Prof. Peter L. Andersen, Statens Serum Institut, Copenhagen, Denmark
Starting date: 01 November 2017
Duration: 60 months
Grant amount: EUR 13,788,161
Grant agreement: RIA2016V-1631
Project website
PrEPVacc
A combination effect study in Africa of two DNA-MVA- or DNA- Env protein HIV-1 vaccine regimens with pre-exposure prophylaxis (PrEP)
Imperial College of Science, Technology and Medicine (Imperial College), London, United Kingdom with partners from Germany, Sweden, Mozambique, South Africa, Switzerland, Tanzania, Uganda, United Kingdom, and United States
Project coordinator: Prof. Jonathan Weber, Imperial College, United Kingdom
Starting date: 1 January 2018
Duration: 63 months
Grant amount: EUR 14,999,955
Grant agreement: RIA2016V-1644
See also the AVAC web page or the ERA LEARN web page
PREV-PKDL
Clinical development of a therapeutic vaccine for prevention of post-kala azar dermal leishmaniasis
European Vaccine Initiative – EWIV (EVI), Heidelberg, Germany with partners from Ethiopia, Kenya, Sudan, Uganda, and United Kingdom
Project coordinator: Dr Sophie Houard, EVI, Germany
Starting date: 1 April 2018
Duration: 63 months
Grant amount: EUR 8,000,476
Grant agreement: RIA2016V-1640
Project website
priMe
A multicentre phase III double-blind, randomised, controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG
Vakzine Projekt Management GmbH (VPM), Hannover, Germany with partners from Gabon, India, Kenya, the Netherlands, South Africa, Tanzania, and Uganda
Project coordinator: Dr Leander Grode, VPM, Germany
Starting date: 1 May 2018
Duration: 60 months
Grant amount: EUR 12,492,521
Grant agreement: RIA2016V-1645
Project website